Fecal Microbiota Transplantation for Parkinson's Disease

University Ghent49 enrolled

Overview

Parkinson's disease (PD) is the second most common neurodegenerative disorder and due to the lack of early diagnosis and effective therapy, represents a large burden for our society and healthcare system. The last years, it became increasingly apparent that non-motor symptoms, including gastrointestinal dysfunction, precede the onset of the typical PD motor symptoms by several years. Moreover, emerging evidence suggests that PD, and more specifically the aggregation of alpha-synuclein, starts in the gut before spreading to the brain. Additionally, recent microbiome studies consistently showed microbiota differences between PD patients and healthy controls. The ultimate goal of this project is to address the impact of gut dysbiosis and the restoration of gut homeostasis by fecal microbiota transplantation (FMT) on the development and progression of PD. We will identify PD-specific changes in microbiota composition and gut inflammation and determine the effect of a 'microbiome-reset' approach through FMT in PD patients on the identified changes and more importantly on disease symptoms and progression.

In this study the effects of fecal microbiota transplantation (FMT) on patients with Parkinson's disease will be investigated in a double-blind, placebo-controlled randomized clinical trial. At time of FMT, forty patients will be randomized in a double-blinded fashion to the treatment arm (healthy donor stool) or placebo arm (own stool). Transplantation will be performed through nasojejunal administration. Donors for this study will be recruited from a healthy donor pool who will donate stool after clearance of a strict inclusion protocol which will assess the presence of any infectious diseases. Donor stool will be frozen and stored until day of FMT. Participants will be screened for relevant inclusion and exclusion criteria and will have to sign an informed consent before admission to the study. Prior and on a regular basis following the FMT participants will be evaluated through neurological clinical examination and standardized clinical scoring scales including MDS-UPDRS, PDQ-39, NMSS and MoCA. Stool samples will be taken regularly and stored at -80°C for microbiome analysis. Blood will be collected for determining relevant markers. All participants will also undergo sampling for oral and nasal microbiome. Follow-up will continue for a total duration of one year. Prior to FMT, all participants will undergo a colonoscopy to exclude contra-indications for FMT and to collect mucosa-adherent microbial samples and gastrointestinal tissue biopts. This colonoscopy will be repeated once, one year following the FMT. The primary endpoint in this study will be a change in clinical status measured through the MDS-UPDRS. Additionally, motor and non-motor symptoms will be correlated with serum markers of inflammation and gut and central nervous system barrier function, microbiota changes and gastrointestinal biopsy analysis of inflammation.

Interventions

Donor FMTOTHER

Fecal microbiota transplantation through nasojejunal administration. Fecal matter will be collected prior to the start of the study from healthy donors and will be frozen at -80°C after thorough screening for infectious diseases. At the time of transplantation, samples will be thawed and administrated to the patients in the treatment group.

Autologous FMTOTHER

Fecal microbiota transplantation through nasojejunal administration. Fecal matter will be collected prior to the start of the study from each patient and will be frozen at -80°C after thorough screening for infectious diseases. At the time of transplantation, samples will be thawed and administrated to the patients in the control group.

Eligibility

Sex: ALLMin age: 50 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria for patients: * Signed informed consent. * Clinical PD diagnosis (MDS criteria) * Hoehn \& Yahr score of 2-3 in OFF * Age of motor symptoms onset \> 50 years Exclusion Criteria for patients: * First degree relative or more than one relative with PD * Diagnosis of dementia or MMSE \< 25 * Diagnosis of major depression or psychosis (DSM-V criteria) * Any of the following within the previous 2 months: hospital admission, narcosis or sedation, abdominal trauma * Primary disease of gastrointestinal tract (exception: chronic gastritis) * Previous abdominal or anorectal surgery (causing structural abnormalities of the intestines) * Any of the following within the previous 2 months: gastrointestinal or respiratory tract infection, food intoxication * The use of probiotics or antibiotics within three months prior to FMT * Contra-indications for colonoscopy * Other immune disorder or clinical immunosuppression * Drug abuse * Malignancy * Any severe comorbidity that might interfere with the study course as determined by the treating physician * Pregnancy or inadequate anti conception for the duration of the trial Inclusion criteria for donors * age 18 - 75 years * signed informed consent * normal screening protocol, including screening for infectious diseases, according to the recommendations of the Superior Health Council of Belgium concerning the safety and quality of fecal transplantation in humans Exclusion criteria for donors * presence of gastrointestinal symptoms * gastro-intestinal or other important comorbidity * obesity or metabolic syndrome * history of malignancy both gastrointestinal or systemic * presence of known colon polyps * recent placing of piercings/tattoos * sexual risk behaviour * antimicrobial therapy 3 months prior to donation * living in the same household as a Parkinson's disease patient

Outcomes

Primary Outcomes

Changes in clinical symptoms as scored on the MDS-UPDRS (Movement Disorder Society - Unified Parkinson's Disease Rating Scale)

The MDS-UPDRS (Movement Disorder Society - Unified Parkinson's Disease Rating Scale) has four parts: Part I (non-motor experiences of daily living; 13 items), Part II (motor experiences of daily living; 13 items), Part III (motor examination; 33 scores based on 18 items, several with right, left or other body distribution scores) and Part IV (motor complications; 6 items). Each item has 0-4 ratings, where 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe. Part III will be clinically scored in an OFF-medication state. Subscales are analyzed separately. References: 1. Goetz, C. et al. Movement Disord 22, 41-47 (2007). 2. Goetz, C. et al. Movement Disord 23, 2129-2170 (2008).